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Abstract
Rationale: Inflammatory mechanisms have been suggested to play a role in the development of heart failure (HF), but a role
for chemokines is largely unknown. Based on their role in inflammation and matrix remodeling in other tissues, we
hypothesized that CXCL13 and CXCR5 could be involved in cardiac remodeling during HF.
Objective: We sought to analyze the role of the chemokine CXCL13 and its receptor CXCR5 in cardiac pathophysiology
leading to HF.
Methods and Results: Mice harboring a systemic knockout of the CXCR5 (CXCR5
2/2) displayed increased mortality
during a follow-up of 80 days after aortic banding (AB). Following three weeks of AB, CXCR5
2/2 developed significant
left ventricular (LV) dilatation compared to wild type (WT) mice. Microarray analysis revealed altered expression of several
small leucine-rich proteoglycans (SLRPs) that bind to collagen and modulate fibril assembly. Protein levels of
fibromodulin, decorin and lumican (all SLRPs) were significantly reduced in AB CXCR5
2/2 compared to AB WT mice.
Electron microscopy revealed loosely packed extracellular matrix with individual collagen fibers and small networks of
proteoglycans in AB CXCR5
2/2 mice. Addition of CXCL13 to cultured cardiac fibroblasts enhanced the expression of
SLRPs. In patients with HF, we observed increased myocardial levels of CXCR5 and SLRPs, which was reversed following
LV assist device treatment.
Conclusions: Lack of CXCR5 leads to LV dilatation and increased mortality during pressure overload, possibly via lack of an
increase in SLRPs. This study demonstrates a critical role of the chemokine CXCL13 and CXCR5 in survival and maintaining of
cardiac structure upon pressure overload, by regulating proteoglycans essential for correct collagen assembly.
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Introduction
Heart failure (HF) is a disorder associated with low-grade
immune activation and inflammation, as evidenced by elevated
circulating and myocardial levels of inflammatory cytokines,
including tumor necrosis factor (TNF)a, interleukin (IL)-1b and
IL-18, and chemokines such as monocyte chemoattractant protein
(MCP)-1 and fractalkine [1–5]. A range of experimental studies
have also suggested a pathogenic role for several of these
inflammatory mediators in the development and progression of
HF [4,6–8]. However, the role of inflammation in HF remains
incompletely understood. Identification of the most important
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18668mediators of the inflammatory pathways involved in the
pathogenesis of HF and their mechanism of action are issues that
need to be further clarified.
While most chemokines have been linked to inflammatory
processes in peripheral tissue, the homeostatic chemokines (i.e.,
CCL19, CCL21, and CXCL13) and their corresponding recep-
tors (i.e., CCR7 for [CCL19 and CCL21] and CXCR5 for
[CXCL13]) have been associated with development and mainte-
nance of secondary lymphoid organs [9–12], as well as the entry
of lymphocytes and dendritic cells to secondary lymphoid tissue
[13–15]. Recently, however, reports have pointed to a broader
role for these homeostatic chemokines, including modulation of
inflammatory and anti-inflammatory responses in lymphoid and
non-lymphoid tissue. Thus, while CXCL13 was known to dictate
homing and motility of B cells in lymphoid tissue, more recent
studies suggest that CXCL13 is involved in the formation of
ectopic lymphoid tissue in chronic inflammation [16,17]. This
chemokine has also been linked to T cell [9,18,19] and monocyte
activation [20] and apoptosis [21]. In line with its newly dis-
covered role in the immune system, CXCL13 has been suggested
to be involved in the pathogenesis of rheumatoid arthritis [22],
Sjo ¨gren syndrome [23–25], inflammatory bowel disease [26], and
multiple sclerosis [27]. CXCR5 is a G protein-coupled seven
transmembrane receptor and belongs to the CXC chemokine
receptor family [28]. Recently, CXCR5 has been found to be
involved in remodeling of extracellular matrix (ECM) in various
types of cancer, including colon [29] and prostate cancer [30].
However, the potential role for CXCL13 and CXCR5 in the
pathogenesis of myocardial remodeling has not been studied.
Based on their potential role in inflammation and matrix
remodeling, we hypothesized that CXCL13 and its receptor
CXCR5 are involved in cardiac remodeling and development of
HF. We examined this hypothesis by studying the cardiac
morphology, function and molecular alterations in CXCR5
deficient (CXCR5
2/2) mice exposed to left ventricular (LV)
pressure overload induced by aortic banding (AB).
Results
Expression of CXCR5 and CXCL13 in murine hearts
We first examined if the CXCL13/CXCR5 dyad was regulated
during AB in mice. Both CXCL13 and CXCR5 were expressed
within the murine heart, and as shown in Fig. 1A and B, we found
significantly enhanced myocardial expression of CXCR5, but not
of CXCL13, in mice that underwent AB as compared with sham
operated mice. Within the myocardium, we found mRNA
expression of CXCL13 and CXCR5 in cardiomyocytes, fibro-
blasts and endothelial cells with the highest expression of both
CXCR5 and CXCL13 in myocardial fibroblasts (Fig. 2A, B).
Survival during LV pressure overload
As depicted in Kaplan-Meier survival curves (Fig. 3), CXCR5
2/2
mice exhibited significantly higher mortality rates than WT mice
during an 80-day follow-up after AB induction. The differences in
mortality emerged after 40 days of AB.
Severe LV dilatation in CXCR5
2/2 mice following
pressure overload
To investigate a potential role for CXCR5 in cardiac
remodeling and development of HF, we evaluated cardiac
morphology and function in WT and CXCR5
2/2 mice. Two-
dimensional and M-mode echocardiography performed in non-
operated WT (n=6) and CXCR5
2/2 (n=6) mice showed no
significant differences in LV function or dimensions (Table S1).
Twenty-one days after AB, echocardiographic assessment showed
comparable increases in flow velocities across the banded region of
the aorta in the WT and CXCR5
2/2 groups. However, LV
fractional shortening was reduced by 65% in CXCR5
2/2 mice,
but only by 13% in WT (Table S1). The mean LV diastolic
dimension was significantly larger and the LV posterior wall
thickness was significantly lower in CXCR5
2/2 mice compared to
WT mice at the same time point (Fig. 4A, B).
CXCR5
2/2 mice show increased expression of
hypertrophy maker genes in response to pressure
overload
Despite similar increases in heart weight to tibial length (HW/
TL) ratio in both genotypes after AB, CXCR5
2/2 mice exhibited
a more marked increase in expression of ANP (3.3-fold increase),
BNP (2.3-fold increase) and b-MHC (2.5-fold increase) than
WT (Fig. S1A–C). The marked increase in ANP and BNP in
CXCR5
2/2 mice following AB might suggest increased myocar-
dial wall stress in these mice.
CXCR5
2/2 mice exhibit major alterations in ECM in
response to pressure overload
Since alterations in extracellular matrix (ECM) might be
responsible for LV dilatation, we examined the quality and
composition of the ECM following AB. CXCR5
2/2 mice
exhibited increased myocardial collagen content following AB as
compared with WT mice, as illustrated by both Masson trichrome
staining (Fig. 5A) and hydroxyproline measurement by HPLC
(Fig. 5B). This increase in collagen content in CXCR5
2/2 mice
Figure 1. Myocardial gene expression of CXCL13 and CXCR5 in mice. Myocardial gene expression of (A) CXCL13 and (B) CXCR5 in wild type
(WT) Sham (n=7) and WT aorta banded (AB) (n=14) group. The results are mean 6 SEM. **p,0.01 vs. Sham group.
doi:10.1371/journal.pone.0018668.g001
CXCL13/CXCR5 in Heart Failure
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18668was accompanied by a significant increase in total matrix
metalloproteinase (MMP) activity (Fig. 5C) and gelatinolytic
activity (Fig. 5D, E). This combination of increased collagen
content and increased MMP activity suggest enhanced matrix
remodeling in CXCR5 deficient mice following AB.
Microarray analysis identified altered expression of genes
encoding non-collagen ECM proteins
In addition to collagen, the quantity and quality of other ECM
constituents also importantly influence cardiac function [31]. We
therefore performed microarray analysis (Affymetrix) of the
myocardium from WT and CXCR5
2/2 mice 3 weeks after AB.
The seeded Bayesian network method [32] was used to explore
interactions between differentially expressed genes. This analysis
identified a cluster of genes encoding ECM proteins. Interestingly,
this cluster contained fibromodulin which belongs to a family of
small leucine-rich repeat proteoglycans (SLRPs), which are known
to influence ECM assembly [33]. Microarray data are accessible
through GEO Series accession number GSE22295 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22295).
Protein levels of SLRPs following AB in CXCR5
2/2 and WT
mice
To further examine the regulation of SLRPs following AB, we
measured protein levels of fibromodulin and other members in the
SLRP family, including decorin, lumican and biglycan. With the
exception of biglycan, all of these SLRPs were differently regulated
in CXCR5
2/2 mice compared to WT mice following AB (Fig. 6).
While decorin and lumican markedly increased during AB in WT
mice, this was not observed in CXCR5
2/2 mice (Fig. 6A, B).
Moreover, while fibromodulin decreased following AB in WT and
CXCR5
2/2 mice, the decrease was significantly more pro-
nounced in the CXCR5
2/2 mice (Fig. 6C).
Electron microscopic analysis revealed loosely packed
ECM in CXCR5
2/2 mice following AB
SLRPs are capable of binding to different types of collagen
[34,35], thereby regulating fibril assembly and organization,
degradation, and quantitative and functional aspects of the
collagen network [33]. To further elucidate the effect of decreased
levels of SLRPs during pressure overload, LV tissue sections were
examined by electron microscopic analysis in WT and CXCR5-
deficient mice. As shown in Fig. 6D and E, a considerable increase
in the extracellular space was observed in LVs from CXCR5
2/2
as compared to WT mice. In addition, banded WT mice exhibited
densely packed collagen fibers of variable thickness and orientation
as well as proteoglycan particles associated with fine filaments
(Fig. 6F). In contrast, the ECM in CXCR5
2/2 mice exhibited
large areas with a coarse network of individual collagen fibrils, and
finer networks of proteoglycans with associated filaments (Fig. 6G),
suggesting deranged ECM.
No difference in apoptosis and leukocyte infiltration
between CXCR5
2/2 and WT mice after pressure overload
CXCL13 has been suggested to exhibit anti-apoptotic proper-
ties [36,37]. However, analysis of cardiac apoptosis by in situ
TUNEL staining revealed that, after either sham-operation or AB,
the number of apoptotic cells was similar in WT and CXCR5-
deficient mice (Fig. S2). Moreover, although CXCL13 is known to
influence lymphocyte trafficking [38,39], we found no significant
Figure 2. Gene expression of CXCL13 and CXCR5 in myocardial cells in mice. Gene expression of (A) CXCL13 and (B) CXCR5 in
cardiomyocytes, fibroblasts and endothelial cells from wild type mice (n=3). mRNA levels were assesssed by quantitaive real time PCR. AU=Arbitrary
unit. The results are mean 6 SEM. * p,0.05, **p,0.01, ***p,0.001 vs. cardiomyocytes. {{p ,0.01 vs. fibroblasts.
doi:10.1371/journal.pone.0018668.g002
Figure 3. Kaplan-Meier survival curves of wild type (WT)
(n=20) and CXCR5
2/2 mice (n=20) after aortic banding (AB).
Echocardiographic assessment showed comparable increases in flow
velocities across the banded region of the aorta in WT and CXCR5
2/2
twenty-one days after primary surgery. Differences in survival between
WT and CXCR5
2/2 mice were tested with the log-rank test. *p,0.05 vs.
WT.
doi:10.1371/journal.pone.0018668.g003
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+ or CD45
+ cells between
CXCR5
2/2 and WT mice after either sham operation or AB
(Fig. S3A and B).
CXCL13 stimulates expression of SLRPs
The changes in ECM in CXCR5
2/2 mice following AB,
consisting of enhanced MMP activity and decreased expression of
several SLRPs, could potentially reflect direct effects of CXCL13
on myocardial fibroblasts. In fact, both CXCL13 and CXCR5
were strongly expressed within myocardial fibroblasts, and
CXCR5 showed enhanced myocardial expression during AB in
WT mice (Fig. 1). In addition, fibroblasts are important producers
of ECM proteins, including SLRPs. Stimulation of cardiac
neonatal rat fibroblasts with CXCL13 did indeed enhance the
expression of fibromodulin, biglycan and lumican, and in
particular of decorin, and at the same time down-regulated total
MMP activity (Fig. 7A, B).
CXCL13-CXCR5 mediate their effects on matrix
modulation via ERK1/2 signaling
We next examined alterations in the ERK1/2 pathway in
CXCR5
2/2 following AB, as this pathway is of importance in
cardiac remodeling and since CXCL13 signaling through CXCR5
is known to activate the MAPK pathway via ERK 1/2 [40,41]. As
shown in Fig. 7C and D, LV from CXCR5
2/2 mice showed
decreased levels of phosphorylated ERK1/2 as compared with
WT mice. In cardiac fibroblasts, blocking the ERK1/2 pathway
by UO126, a highly selective inhibitor of MEK 1 and 2,
significantly attenuated up-regulation of fibromodulin following
CXCL13 treatment (Fig. 7E).
Expression of CXCR5 and SLRPs in patients with HF
Assessments of CXCR5 mRNA levels in myocardial tissue from
9 HF patients (all with advanced HF, NYHA class IV) and 5
controls (non-failing hearts) showed that HF patients had markedly
enhanced gene expression of CXCR5 (84% increase, p,0.005).
As shown in Fig. 7, the 9 HF patients also had significantly
enhanced gene expression of biglycan, lumican and fibromodulin.
When the HF patients were treated with continuous-flow LV assist
device (LVAD) for 861.7 months, improvement in hemodynamic
parameters (LV end diastolic volume decreased from 294.9 mL to
237.8 mL, LV diastolic diameter from 7.6 cm to 6.8 cm, and LV
end systolic volume from 244.8 mL to 183.4 mL, reflected in an
increase in LVEF from 18.2 to 29.6%, p,0.05 for all) was
accompanied by a marked decrease in mRNA levels of CXCR5 as
well as biglycan and fibromodulin, although the decrease in
fibromodulin did not reach statistical significance (Fig. 8).
Discussion
Despite observations of enhanced levels of chemokines and their
corresponding receptors in human HF [5,42,43], the role of
chemokines in maintaining cardiac structure and function has
never been established. The present work clearly demonstrates that
the chemokine CXCL13 and its receptor, CXCR5, are critically
involved in cardiac remodeling. The key results of this study were
increased mortality and severe LV dilatation in CXCR5-deficient
mice in response to pressure overload, potentially resulting from
impaired quality of ECM. These ECM alterations derived, at least
partly from decreased SLRP levels and enhanced MMP activity
within the myocardium. Our in vitro findings showed that CXCL13
can promote SLRP expression and attenuate MMP activity in
myocardial fibroblasts. Therefore, the opposite pattern seen in
CXCR5-deficient mice could reflect the inability of their
myocardial fibroblasts to respond to CXCL13. These data indicate
that the CXCL13/CXCR5 interaction is involved in myocardial
remodeling following pressure overload, possibly by regulating
proteoglycans crucial for the quality of myocardial ECM. Our
findings of a strong expression of CXCL13 and CXCR5 in
fibroblasts within murine hearts and enhanced myocardial
expression of CXCR5 during AB further support such a notion.
The possible role of chemokines in the pathogenesis of HF has,
at least in part, been attributed to the ability of these molecules to
promote leukocyte infiltration in failing myocardium. However, in
the present study we did not detect altered infiltration of CD3
+
and CD45
+ cells in CXCR5
2/2 mice compared to the WT mice
following AB. Previously, various chemokines (e.g., CXCL16,
MCP-1 and CX3CL1) have been shown to promote direct effects
on myocardial fibroblasts and cardiomyocytes in vitro [5,43–45].
Also, the lack of CXCR4 has been associated with severe
myocardial developmental defects (i.e., ventricular septum defects)
[46]. In contrast to CXCR4, CXCR5 deficient mice are viable
and display normal morphology and function of the adult heart.
However, our present data showing a markedly dilating
myocardial phenotype in CXCR5
2/2 mice exposed to pressure
Figure 4. Left ventricular (LV) dilatation in CXCR5
2/2 mice 3 weeks following aortic banding (AB). LV inner diameter (A) and thickness of
the posterior wall (B) were measured in the wild type (WT) Sham (n=6), CXCR5
2/2 Sham (n=6), WT AB (n=6), and CXCR5
2/2 AB (n=6) groups. The
results are mean 6 SEM. *p,0.05 and ***p,0.001 vs. Sham groups; {{p,0.01 and {{{p,0.001 vs. WT AB group.
doi:10.1371/journal.pone.0018668.g004
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infiltration, may suggest a direct involvement of CXCL13/
CXCR5 activation in myocardial remodeling. The ability of
CXCL13 to attenuate MMP activity and increase SLRP
expression in myocardial fibroblasts as well as the up-regulation
of CXCR5 during AB in WT mice further supports such a notion.
Figure 5. Extracellular matrix remodeling in wild type (WT) and CXCR5
2/2 mice following aortic banding (AB). Collagen content in
myocardium examined with (A) Masson trichrome staining in representative sections from AB WT and CXCR5
2/2 mice and (B) by hydroxyproline
measurement in WT Sham (n=13), CXCR5
2/2 Sham (n=12), WT AB (n=13) and CXCR5
2/2 AB (n=14) groups. (C) Total MMP activity in percentage of
the WT Sham group (n=11) measured in the CXCR5
2/2 Sham (n=13), WT AB (n=9), and CXCR5
2/2 AB groups (n=9). (D) Gelatinolytic activity of
MMP-2 relative to the WT Sham group (n=5) measured in the CXCR5
2/2 Sham (n=5), WT AB (n=5), and CXCR5
2/2 AB groups (n=5) and of (E) MMP-
9 relative to the WT Sham group (n=6) measured in the CXCR5
2/2 Sham (n=6), WT AB (n=8), and CXCR5
2/2 AB groups (n=9). The results are mean
6 SEM. *p,0.05, **p,0.01 and ***p,0.001 vs. Sham groups; {p,0.05 and {{p,0.01 vs. WT AB groups.
doi:10.1371/journal.pone.0018668.g005
CXCL13/CXCR5 in Heart Failure
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be finely tuned, as an imbalance in these processes might result in
cardiac dilatation, cardiac hypertrophy and fibrosis. Although we
observed increased total collagen content in CXCR5
2/2 mice,
these mice were also characterized by massively disturbed
structural frameworks after AB compared to WT. Our molecular
analysis suggested that this distorted ECM structure derives from a
failure in the regulation of SLRPs in pressure overloaded CXCR5-
deficient mice. SLRPs are known to bind to collagens, and in so
doing, regulate the self-assembly process of pro-collagen into fibrils
[33–35]. This assembly is necessary for covalent cross-linking
which is required for reinforcement of the collagen fibrils. SLRPs
have been shown to be up-regulated in the infarcted area in rats
and mice following myocardial infarction (MI) [47,48]. Studies in
SLRP deficient mice have shown abnormal fibril organization and
loose fibril packing in the MI scar [49,50]. In the current study we
show an attenuated up-regulation (i.e., decorin and lumican) and a
more pronounced decrease (i.e., fibromodulin) in SLRP expression
following AB in CXCR5 deficient mice as compared with WT
mice. Interestingly, enhanced MMP activity has been found to
impair SLRP function [44], and we suggest that the combination
of decreased SLRP expression and increased MMP activity could
be of major importance for the premature LV dilatation and HF
in CXCR5
2/2 mice following AB.
Our in vitro data suggest that CXCL13 via activation of CXCR5
on myocardial fibroblasts induces the expression of SLRPs
through the ERK1/2 pathway. This mechanism appears to be
absent in fibroblasts from CXCR5
2/2 mice. ERK is one of the
key protein kinases that regulate growth and proliferation of
cardiac fibroblasts [40]. In line with a crucial role of CXCL13/
CXCR5-mediated ERK1/2 activation for cardiac remodeling in
response to pressure overload, ERK1/2 phosphorylation was
substantially lower in CXCR5
2/2 mice compared to WT after
AB. These findings further support previous reports of a central
role of the ERK pathway for myocardial remodeling [51,52]. In
this regard, the present study adds a novel component to this
pathway by linking CXCR5-mediated effects to SLRPs and
subsequent ECM remodeling.
Our studies in patients with advanced HF suggest that our
findings in experimental HF may have relevance to clinical HF.
We showed enhanced myocardial expression of CXCR5 and
certain SLRPs (i.e., biglycan, lumican and fibromodulin) in the
failing myocardium, and notably, biglycan and lumican were
down-regulated following the clinical and hemodynamic improve-
ment during treatment with LV assist device. Based on our
experimental data, it is tempting to speculate that CXCR5
activation promotes protective responses in ECM in failing
myocardium involving enhanced expression of SLRPs. As
Figure 6. Protein levels of small leucine-rich repeat proteoglycans (SLRPs) and transmission electron microscopic analysis in wild
type (WT) and CXCR5
2/2 mice following aortic banding (AB). Protein levels of (A) decorin and (B) lumican in (WT) Sham (n=7), CXCR5
2/2
Sham (n=5), WT AB (n=6), and CXCR5
2/2 AB (n=5), and (C) fibromodulin in WT Sham (n=13), CXCR5
2/2 Sham (n=12), WT AB (n=12), and
CXCR5
2/2 AB (n=11) groups as assessed by western blotting. The upper panels show representative blots from two mice in each group.
1 Glycosylated forms of decorin and lumican, respectively. The results are mean 6 SEM. *p,0.05, **p,0.001 and ***p,0.001 vs. Sham groups;
{p,0.05 and {{p,0.01 vs. WT AB group. The lower panels show representative transmission electron micrographs of the LV free wall at 6440 and
623000 magnification in WT (D and F) and CXCR5
2/2 (E and G) AB mice.
doi:10.1371/journal.pone.0018668.g006
CXCL13/CXCR5 in Heart Failure
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18668myocardial function improves, this response is attenuated. At
present, however, the stimuli for enhanced myocardial CXCR5
expression in HF and the interpretation of our human data will
require further investigation.
In conclusion, we have found that CXCR5 plays an important
role in cardiac remodeling during pressure-overload. Loss of
CXCR5 in this situation adversely affects matrix remodeling and
causes LV dilatation, possibly through altered regulation of
proteoglycans crucial for the quality of myocardial ECM (i.e.,
SLRPs) as well as through enhanced MMP activity. These changes
could, at least in part, be attributed to loss of CXCL13 mediated
effects on myocardial fibroblasts in CXCR5 deficient mice. The
Figure 7. Effects of CXCL13 on gene expression of small leucine-rich repeat proteoglycans (SLRPs), total MMP activity and the
intracellular signalling pathway ERK 1/2 in neonatale rat fibroblasts (FB). The effect of CXCL13 (200 ng/ml) stimulation on gene expression
of (A) decorin, biglycan, lumican and fibromodulin (n=4) in myocardial FB after 20 hours of stimulation in relation to GAPDH and (B) total MMP
activity in cell-free supernatant (n=7) after 20 hours of stimulation. The ratio of phosphorylated ERK 1/2 (p-ERK 1/2) to total ERK 1/2 assessed by (C)
western blotting in WT Sham (n=13), CXCR5
2/2 Sham (n=12), WT AB (n=11), and CXCR5
2/2 AB (n=10) groups, and by (D) BioPlex in WT Sham
(n=6), CXCR5
2/2 Sham (n=5), WT AB (n=7), and CXCR5
2/2 AB (n=6) groups. (E) The effect of blocking ERK 1/2 activation with UO126 (10 mM) on
the CXCL13-mediated induction of fibromodulin gene expression in myocardial FB (n=4). The results are mean 6 SEM. *p,0.05 and **p,0.01 vs.
unstimulated FB or CXCR5
2/2 Sham; {p,0.05 vs. WT AB group, {p,0.05 vs. CXCL13 stimulated FB without inhibitor (UO126).
doi:10.1371/journal.pone.0018668.g007
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dilatation during pressure overload is of major importance for the
development of new treatment strategies in HF related to
hypertension and aortic stenosis. Future studies should examine
how the CXCL13/CXCR5 dyad could be utilized therapeutically
in clinical HF.
Materials and Methods
Ethics
All animal experiments were approved by the Norwegian
Animal Research Committee (ID 1902) and conform to the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–23, revised
1996). The part of the study that involved humans was approved
by the local ethics committee (REK Helse Sør-Øst) and conducted
according to the ethical guidelines outlined in the Declaration of
Helsinki for use of human tissue and subjects. Informed written
consent was obtained from all subjects. The authors had full access
to the data and take responsibility for its integrity. All authors have
read and agree to the manuscript as written.
Data analysis
All data are expressed as group means 6 SEM unless indicated
otherwise. For comparisons of 2 groups, the Mann-Whitney U test
was employed. The Wilcoxon test was employed when analysing
the effect of LVAD treatment. Differences between the WT Sham,
WT AB, CXCR5
2/2 Sham, and CXCR5
2/2 AB groups were
determined by one-way ANOVA with post-hoc Tukey test.
Differences in survival between wild type and CXCR5
2/2 mice
in Fig. 3 were compared using Kaplan- Meier survival curves and
tested with the log-rank test. All tests were employed using a 5%
significance level.
Animals and AB protocol
Mice were housed in M2 or M3 cages with Bee Kay bedding
(Scanbur BK, Nittedal, Norway) in 55% humidity on a 12 h light/
dark cycle. Food pellets (RM1, 801151, Scanbur BK) and water
were freely available. All mice utilized in this study were male and
had a weight 20–30 g. WT C57BL/6 mice were obtained from
Taconic (Skensved, Denmark). The generation of CXCR5
2/2
mice (C57BL/6 background, now accessible at the Jackson
Laboratory, stock number 006659, strain name B6.129S2 (Cg)-
Cxcr5
tm1Lipp/J has been described previously [14]. Briefly, gene
targeting was performed in 129S2/SvPas-derived D3 embryonic
stem cells, replacing the coding region of the CXCR5 gene with a
neomycin resistance gene. Mutant mice were backcrossed to
C57BL/6 mice for 8 generations. AB was induced in C57BL/6
and CXCR5
2/2 mice as previously described [53]. Briefly, after
being anesthetized with 5% isoflurane and ,98% oxygen in a gas
chamber, the animals where endotracheal intubated and the
cannula was connected to a volume cycled rodent ventilator
(Harvard Apparatus) on supplement of a mixture of ,1.75%
isoflurane and ,98% oxygen. A thoracotomy was performed in
the second intercostal space on the left side, and the aortic
constriction was created by placing a ligature securely around the
ascending aorta and a 26-gauge needle and then removing the
needle. Sham operated animals underwent the same procedure
except for aortic constriction. The animals were extubated after
getting a dose of analgesic (buprenorphine, 0.1 mg/kg) subcuta-
Figure 8. Gene expression of CXCR5, biglycan, lumican and fibromodulin in patients with heart failure (HF) (n=9) and controls
(n=5) as assesssed by quantitaive real time PCR. In the HF patients, the mRNA levels were measured before and after treatment with
continuous-flow left ventricular assist device (LVAD).
doi:10.1371/journal.pone.0018668.g008
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performed 21 days after primary surgery under general anaesthe-
sia with isoflurane as described above. This time point was selected
since previous studies in our laboratory have shown marked
hypertrophy in WT mice at this stage. AB mice in both groups
with a flow velocity across the aortic banding site greater than
3.5 m/s were included in the study. The same mice anesthetized
with isoflurane were euthanized by dislocation of the neck, and the
hearts and lungs were removed and blotted dry. The right
ventricle and atria were removed. The LV, right ventricular free
wall and lungs were weighed and normalized to tibial length.
Doppler Echocardiography
Mice were examined while sedated in the supine position with
the chest closed, as previously described [54]. Echocardiography
was performed using a i13L 13 MHz linear array transducer (GE
Healthcare Technologies, Oslo, Norway) and data were analyzed
with EchoPac PC software (GE Healthcare Technologies, Oslo,
Norway) as described [55]. The data were recorded and analyzed
by a cardiologist (IS), blinded for the genotype.
Isolation of adult myocardial murine cardiomyocytes,
fibroblasts and endothelial cells
Mouse cardiomyocytes were isolated as previously described
[56]. Endothelial cells were enriched from the non-cardiomyocyte
fraction by labeling the cells with a rat anti-mouse CD31 antibody
(eBioscience, San Diego, CA) and subsequent extraction using an
anti-rat secondary antibody coupled to magnetic beads (Miltenyi
Biotec, Auburn, CA) and further column purifications according
to the protocols provided by the manufacturer (http://www.
miltenyibiotec.com). The cell fraction remaining after extraction of
cardiomyocytes and endothelial cells contains predominantly
fibroblasts.
RNA isolation
Total RNA was isolated from the LV in WT and CXCR5
2/2
mice (SV total RNA isolation system, Promega, Inc., Madison,
WI), mouse and neonatal rat cardiomyocytes and fibroblasts, and
mouse endothelial cells (RNeasy mini kit, Qiagen, Valencia, CA)
as previously described [5].
Quantitative real-time PCR (qRT-PCR)
Reverse transcription reactions were performed with iScript
Select cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules,
CA). Pre-designed TaqMan assays (Applied Biosystems,
Foster City, CA) were used to determine gene expression
of CXCL13(Mm00444534_m1), CXCR5 (Mm00432086_m1),
ANP (Mm01255748_g1), BNP (Mm00435304_g1), b-MHC
(Mm01319006_g1), biglycan (Rn00567229_m1), fibromodlin
(Rn00589918_m1), lumican (Rn00579127_m1) and decorin
(Rn01503161_m1). The results were detected on an ABI PRISM
7900 Sequence Detection System (Applied Biosystems) as
described previously [5]. In the human studies, quantification of
gene expression was performed using the ABI Prism 7500 (Applied
Biosystems), Power SYBR Green Master Mix (Applied Biosys-
tems), and sequence-specific PCR primers were designed using the
Primer Express software, version 3.0 (Applied Biosystems). List of
the real-time PCR assays used in the human study is shown in
Table S2.
Perfusion fixation and histology
After the hearts were excised and rinsed in cold NaCl solution,
the aorta was cannulated, and the hearts were mounted on a
Langendorff setup, and retrogradely perfused with warm (37uC)
oxygenated Thyrodes solution (5 mM Hepes, pH 7.4, 140 mM
NaCl, 5.4 mM KCl, 0.4 MgH2PO4, 0.5 MgCL2) with 1.8 mM
Ca
2+. Hearts were stopped in diastole by aortic perfusion of
Thyrodes solution with high KCl (10.8 mM) for 3 min and fixated
for 10 min by perfusion of 4% phosphate-buffered formalin. After
the cannulas were removed, fixation by immersion continued for
2 h. Each heart was transected at the midventricular level, and
both halves were routinely processed and embedded in paraffin.
Paired 3.5 mm sections were prepared, mounted on glass slides,
and stained with hematoxylin and eosin and Masson tricrome
stain.
Hydroxyproline analysis
Quantitative analysis of tissue levels of hydroxyproline was
performed by HPLC using the AccQ-Fluor reagent kit (Waters
Corporation, Milford, MA) essentially as previously described
[57]. Briefly, cardiac tissue samples (5 mg dry weight) were
hydrolyzed in 6 M HCl for 16 h at 110uC and subsequently dried
under vacuum and redissolved in the AccQ-Fluor borate buffer.
Derivatization was initiated by addition of the AccQ-Fluor reagent
at 55uC and terminated after 10 min. The samples were finally
subjected to HPLC-chromatography using a 2063.9 mm Sentry
Guard column (Nova-Pak C18 bonded silica) connected to a
15063.9 mm AccQ-Tag reversed-phase column (both from
Waters) according to the manufacturer’s instructions. Derivatized
hydroxyproline was detected by fluorescence signal following
excitation at 250 nm and recording of emission at 395 nm.
Elution of hydroxyproline from myocardial tissue samples was
verified and quantified by co-elution with known amounts of
derivatized hydroxyproline standards (Fluka, Buchs SG, Switzer-
land). The relation of myocardial hydroxyproline contents to
myocardial collagen has previously been reported [58].
Measurements of total MMP activity and gelatinolytic
activity
Total MMP activity in the LV was measured by a fluorogenic
peptide substrate (R&D Systems) used to assess broad-range MMP
activity (MMP-1, -2, -7, -8, -9, -12 and -13 can cleave the peptide).
Gelatinolytic activity was assessed by gelatine zymography. Briefly,
the MMP substrate was diluted in TCN buffer (50 mM Tris HCl,
150 mM NaCl, 10 mM CaCl2; pH 7.5) and added to the
supernatants before incubation at 37uC. After 120 min the total
MMPactivity was determined on a fluorimeter (FLX 800 Microplate
Fluorescence Reader, Bio-Tek Instruments, Winooski, VT).
Gene expression profiling and microarray data analysis
Total RNA was isolated from the LV in Sham (n=3) and AB
(n=4) WT and CXCR5
-/- mice as described previously [5].
Preparation of cRNA and the subsequent steps leading to
hybridization of Affymetrix GeneChipH mouse ST 1.0 arrays
(Affymetrix, Santa Clara, CA), washing, and scanning were
performed according to standard protocols (Affymetrix). Micro-
array preprocessing was done using robust multi-array average
[59]. Differentially expressed genes were found using significance
analysis of microarrays [60]. The seeded Bayesian network
method [32] was used to explore interactions between differen-
tially expressed genes. This method finds interactions in the
expression data using literature co-citations, databases of protein-
protein interactions, as well as co-regulations in the expression
data. We constructed two networks; one for the wild type situation,
using the 60 most differentially expressed genes between AB WT
and SHAM WT, and similarly one for the KO situation, using the
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2/2 AB and
Sham AB. The set of 60 genes were based on a ranking according
to fold change (AB vs. Sham) using a subset of the genes for which
false discovery rate was less than 0.05. All data is MIAME com-
pliant and the following link has been created to allow review of
the data in Gene Expression Omnibus (record GSE22295): http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xdivnmkmeyeiifg&
acc=GSE22295
Western blotting
Western blotting was performed as previously described [61]
with minor modifications. Snap frozen left ventricles from WT and
CXCR5
2/2 mice were homogenized in cell lysis buffer and equal
amounts of protein being separated from each sample by SDS-
PAGE (10%) before transferred to polyvinylidene fluoride (PVDF)
membranes. Non-specific bindings to the membrane was blocked
with 5% BSA for 1 h at room temperature, followed by incubation
with anti-fibromodulin (SC-33772; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), anti-decorin (AF1060; R&D Systems,
Minneapolis, MN), anti-biglycan (AF2667; R&D) or anti-lumican
(AF2745; R&D) overnight at 4uC. The membranes were washed
in TBS-T and followed by species-specific horseradish peroxidase-
coupled secondary antibodies in 5% BSA added for 1 h. After
washing, the immune complexes were visualized by ECL (GE
Healthcare, Buckinghamshire, UK) and the membranes were
exposed to x-ray film (HyperfilmTM ECL, GE healthcare) and
developed. Immunoblots were stripped and re-probed with anti-
GAPDH (C20357; R&D) for normalization. Filters with LV lysate
were also probed with antibody against P-ERK1/2 (Phospho-p44/
42 MAP kinase (Thr 202/Tyr 204), Cell Signaling Technology,
Danvers, MA) or p44/42 MAP kinase (Cell Signaling Technology)
followed by species-specific horseradish peroxidase-coupled sec-
ondary antibodies (Cell Signaling). The immune complexes were
visualized with the use of Supersignal West Pico (Pierce, Rockford,
IL) and exposed films were detected by using Kodak 440 CF
imaging station (Boston, MA). The software Total Laboratory
v.1*10 (Phoretix, Newcastle, UK) was used for quantification.
Transmission electron microscopy
For transmission electron microscopy, hearts (n=2) from each
group were perfused with 2.0% glutaraldehyde buffered in 0.2 M
cacodylate at pH 7.4 for 15 min. Small blocks (about 3 mm
3 in
size) of the LV and septum were taken. The tissues were fixated in
cacodylate buffer for 2 h and washed in the same buffer 3 times.
The blocks of tissue were then transferred to a 1% OsO4 solution
for 10 min on ice. After washing in cacodylate, dehydration was
carried out rapidly in graded ethanol series, followed by
embedding in Epon. Sections were cut at a thickness of 60–
100 nm and collected on 200 mesh grids, and stained with uranyl
acetat for 7 minutes and lead for 3 minutes. The sections were
examined and photographed in a Tecnai G2 spirit BioTWIN
120 kV, LaB6, Transmission Electron Microscope with 4k Eagle
camera from FEI Company. We obtained micrographs of the LV
septum and the free wall at different magnifications.
TUNEL Staining
TUNEL staining was performed on paraffin-embedded sections
using the In Situ Cell Death Detection kit (Roche Diagnostics) as
described [62]. Briefly, paraffin-embedded (6 mm) sections of
mouse hearts were deparaffinized in xylene, rehydrated, and
treated with 0.5% Triton X-100 in 0.1% Na-citrate for 30 min.
After several washes with PBS, the sections were permeabilized
with proteinase K (20 mg/ml in TE, pH 8.0) for 30 min at 37uC.
Subsequently, the sections were rinsed with PBS, and the area
around the sample was dried. TUNEL reaction mixture (50 ml)
containing terminal deoxynucleotidyl transferase was applied and
tissue sections were incubated in a dark, humidified chamber for
1 h at 37uC. After several washes with PBS the tissue sections were
analyzed with a fluorescence microscope (515–565 nm). A
quantitative analysis (number of apoptotic cells/total number of
cells counted) was performed by counting cells in a randomly
selected area of each tissue sample.
Immunohistochemistry
Paired 3.5 mm sections were immunostained using affinity-
purified rabbit polyclonal CD3 antibody (Abcam, Cambridge,
U.K.), dilution 1:400, and anti-mouse/human CD45R (eBioscience,
San Diego, CA), dilution 1:4500. The immune reaction was
visualized using horseradish peroxidase in a Dako Autostainer plus
(Dako, Glostrup,Denmark). We obtained 32 digital images ofevenly
distributed microscopic high power fields (6400) from the left
ventricular free wall and ventricular septum of six heart sections in
each group. The sections were from no less than three hearts in each
group. The 32 images from each heart were studied by two
investigators (AW and HMR), blinded for mouse identity, counting
the total number of CD3 and CD45R positive lymphocytes.
Isolation and stimulation of neonatal myocardial rat
fibroblasts
Primary neonatal fibroblasts were isolated from 1–3 day old
Wistar rats (Taconic, Skensved, Denmark). Briefly, fibroblasts
were separated by Percoll density gradient and transferred to
plating medium and maintained in culture for up to 96 hours. The
fibroblasts were stimulated with human recombinant CXCL13,
200 ng/ml (R&D Systems, Minneapolis, MN), with or without the
ERK1/2 inhibitor (10 mM final concentration UO126 (MEK
inhibitor, Promega, WI)), for 3 and 20 hours before storing cell
pellet (mRNA analyses) and cell-free supernatant (MMP activity)
at 280uC until further analyses. Un-stimulated (control) cells were
also given vehicle. The toxicity in cell cultures was examined
routinely for lactate dehydrogenase leakage using a cytotoxicity
detection kit (Roche Applied Science, Mannheim, Germany).
P-ERK1/2 (Phospho-p44/42 MAP kinase) and ERK1/2
(p44/42 MAP kinase) detection
Phospho-p44/42 MAP kinase and p44/42 MAP kinase levels in
left ventricle lysate were measured by multiplex suspension
array technology using the BioPlex (Bio-Rad, Hercules, CA).
Phospho-p44/42 MAP kinase and p44/42 MAP kinase multi-
plexable beads were purchased from R&D Systems. The quan-
tification was accomplished by using the BioPlex Manager
Software (Bio-Rad).
Tissue sampling from human myocardium
In nine patients with advanced HF (NYHA class IV; 8 male, 1
female; age 2965 years), LV tissue was available at the time of
implantation and at the time of removal (heart transplantation) of
a continuous-flow LV assist device (LVAD; EntrAssist, Ventracor
Ltd, Chatswood, Australia). Average time on LVAD was 861.7
months. Control (non-failing) human LV tissue was obtained from
subjects whose hearts were rejected as cardiac donors for surgical
reasons (n=5). The cause of death of donors was cerebrovascular
accident, and none had a history of heart disease. Myocardium
from these subjects was kept on ice for 1 to 4 hours before tissue
sampling was conducted. In both failing and non-failing
myocardium, LV tissue samples were snap-frozen in liquid
nitrogen, and stored at 280uC until use. None of patients (failing
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such as infection, malignancy, or autoimmune disorder.
Supporting Information
Figure S1 Altered expression of markers of cardiac wall
stress and remodeling. Relative gene expression of (A) atrial
natriuretic peptide (ANP), (B) brain natriuretic peptide (BNP) and
(C) b-myosin heavy chain (MHC) in wild type (WT) Sham (n=6),
CXCR5
-/- Sham (n=6), WT aorta banded (AB) (n=6), and
CXCR5
-/- AB (n=6) groups. The results are mean 6 SEM.
*p,0.05 and ***p,0.001 vs. Sham groups; {p,0.05 and
{{{p ,0.001 vs. WT AB group.
(TIF)
Figure S2 Fluorescent micrographs of sections of left
ventricular myocardium from wild type (WT) and
CXCR5
-/- mice. The arrows indicate TUNEL-positive myocyte
nucleus.
(TIF)
Figure S3 CD45 and CD3 positive lymphocytes in the
left ventricular myocardium from wild type (WT) and
CXCR5
-/- mice. Total number of CD45R (A) and CD3 (B)
postive lymphocytes was not significantly different between
CXCR5
-/- and WT mice after sham operation or AB. (n=6
heart sections in all groups). Cells counted from 32 digital, evenly
distributed images (x400) from each heart.The results are mean 6
SEM.
(TIF)
Table S1 Weights and echocardiographic measure-
ments. Values are means 6 SE. BW, body weight; TL, tibia
length; LVW, left ventricular weight; LW, lung weight; IVSd and
IVSs, interventricular septum thickness in diastole and in systole,
respectively; LVDd and LVDs, left ventricular diameter in diastole
and in systole, respectively; FS, fractional shortening in LVD;
LVPWd and LVPWs, posterior wall thickness in diastole and in
systole, respectively; LAD, left atrial diameter; HR, heart rate;
AVmax, peak aortic stenosis flow velocity; TVs, peak tissue
velocity in systole; TVd, peak tissue velocity in diastole. LVW/TL
and LW/TL are mg/mm. * p,0.05, ** p,0.01, *** p,0.001 vs.
Non-operated and Sham groups. {p,0.05, {{,p,0.01,
{{{p,0.001 vs. WT AB group. {p,0.05 vs CXCR5
-/- Non-
operated group. The results are mean 6 SEM.
(DOC)
Table S2 Characteristics of the real-time PCR assays
used in the human study. The table shows the sequence of
primers used in the real-time PCR assays. (+), forward primers;
(–), reverse primers; Acc.nr, GenBank accession number; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
(DOC)
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